The AVCT share price is currently $0.00, as American Virtual Cloud Technologies, Inc. has been fully liquidated and its common stock canceled following a Chapter 11 bankruptcy process. The company officially delisted from the NASDAQ in early 2023 after filing for voluntary relief, and a subsequent Plan of Liquidation was confirmed on May 23, 2023, which stipulated that equity holders would receive no recovery. While “AVCT” currently exists as a ticker for Avacta Group PLC on the London Stock Exchange (LSE: AVCT), the original American cloud entity has no remaining tradable value or operational assets.
Investors tracking “AVCT” in 2026 should distinguish between the defunct US cloud company and the active UK-based life sciences firm, Avacta Group. For the former, all outstanding shares were nullified on the “Effective Date” of the bankruptcy plan (May 30, 2023), meaning there is no path for price recovery or future trading for previous stockholders of the US entity.
American Virtual Cloud Technologies Bankruptcy
The downfall of AVCT began in late 2022 following a series of liquidity crises and failed strategic pivots. On January 11, 2023, the company and two subsidiaries filed for Chapter 11 bankruptcy in the District of Delaware to facilitate an orderly wind-down.
During the proceedings, the company’s primary asset, Kandy Communications, was sold to Skyvera, LLC (an affiliate of TelcoDR) for approximately $6.78 million in March 2023. This sale effectively stripped the company of its operational core, leaving only a shell for the liquidation process.
The bankruptcy court ruled that the proceeds from asset sales were insufficient to cover the company’s secured and unsecured debts. Consequently, the Chapter 11 Plan of Liquidation officially wiped out all equity interests, leaving common stockholders with zero value.
Delisting and Ticker Symbol Status
American Virtual Cloud Technologies was formerly traded on the NASDAQ under the ticker AVCT. Following its bankruptcy filing, the stock was moved to the over-the-counter (OTC) markets with the ticker AVCTQ before being completely deregistered.
In 2026, many financial platforms still display historical data for AVCT, which can lead to confusion for new investors. It is important to note that the “Q” suffix in bankruptcy-related tickers indicates a company in liquidation, and in the case of AVCTQ, the symbol is now inactive.
The ticker symbol “AVCT” is currently most active on the London Stock Exchange (LSE), representing Avacta Group PLC. This is a completely separate biotech company specializing in oncology drugs and diagnostics, and its share price movements are unrelated to the former US cloud provider.
AVCT Share Price History Highlights
Before its collapse, AVCT experienced significant volatility that attracted retail “meme stock” interest and short-squeeze speculation. At its peak in late 2020, the adjusted share price reached heights above $160 per share (post-split adjustments).
By late 2022, the price had plummeted below $0.20 as the company struggled with high cash burn and a lack of profitable contracts. A 1-for-15 reverse stock split was implemented in late 2022 to maintain NASDAQ listing requirements, but it failed to stop the downward trajectory.
The final trading days on the NASDAQ saw massive volume but minimal price movement, as institutional investors exited their positions. The transition to the OTC market saw the price drop to fractions of a cent before the final cancellation of shares in May 2023.
The Kandy Communications Acquisition
Kandy Communications was the “crown jewel” of AVCT, providing a cloud-based communications-platform-as-a-service (CPaaS). Despite its high-profile partnerships with companies like AT&T, the division was unable to generate sufficient revenue to sustain the parent company’s debt.
The acquisition by Skyvera for $6.8 million was a “stalking horse” bid that was finalized in March 2023. This transaction ensured that the Kandy technology and its customer base survived under new ownership, even as AVCT itself was dissolved.
Skyvera has since integrated Kandy’s assets into its own cloud ecosystem. This means that while the technology lives on, the original investors in AVCT have no legal or financial claim to any profits generated by Kandy under its new parent company.
Risks of “Zombie” Stock Trading
A “zombie” stock refers to a company that has filed for bankruptcy or has no operations but whose ticker still sees occasional “dead cat bounces.” AVCT was a prime example of this during its OTC phase as AVCTQ.
Retail traders often speculate on these stocks hoping for a “reorganization” that includes old shareholders. However, the Plan of Liquidation for AVCT explicitly stated that there would be no “pro rata” distribution to equity holders, making any such speculation 100% loss-prone.
In 2026, any platform claiming to offer “AVCT” (American Virtual Cloud) for purchase is likely displaying a technical error or referring to a different company entirely. Entering into such trades carries extreme risk, as the underlying legal entity no longer exists.
Avacta Group PLC (LSE: AVCT)
If you are seeing a live “AVCT” share price of approximately 70p (Great British Pence), you are looking at Avacta Group PLC on the London Stock Exchange. This company is healthy, operational, and focused on life sciences.
Avacta is known for its pre-CISION platform and Affimer technology, which are used to develop targeted cancer therapies. Its 2026 performance has been driven by Phase 1 clinical trial results and new diagnostic partnerships.
Investors should be careful when using global stock screeners to ensure they have selected the correct exchange. Trading the LSE-listed AVCT involves currency risks (GBP/USD) and different regulatory filings compared to the former NASDAQ-listed entity.
Practical Information for Former Shareholders
If you held AVCT shares during the 2023 bankruptcy, your brokerage account should now reflect a “zero” balance or have removed the ticker entirely. Here is what you need to know for your records.
- Tax Loss Harvesting: Most investors were able to claim a “worthless security” tax deduction for the 2023 tax year. If you have not yet filed for this, consult a professional regarding the look-back period for your jurisdiction.
- Brokerage Statements: Your final 1099-B (or equivalent) from 2023 or 2024 should show the disposition of the shares at a price of $0.00.
- Recovery Prospects: There are no remaining “Class 9” equity committees or legal avenues for recovery. The liquidation is considered closed and final.
Comparing AVCT with sector peers
How AVCT trades vs. other biotechs
When the Avct share price is compared to other small‑cap biotech and diagnostics companies, it typically sits in the mid‑range for volatility and growth expectations. Relative to:
- Pure‑diagnostics peers, AVCT often trades at a higher multiple because of its dual diagnostics–therapeutics model.
- Early‑stage oncology‑only peers, AVCT is sometimes viewed as slightly less risky due to its existing diagnostics‑related revenue base.
Analyst‑coverage tables often show AVCT with a wider price band and higher forecast upside than the sector average, but also with higher downside risk if the company fails to meet its pipeline goals. This “high‑upside, high‑risk” profile is why the Avct share price can swing so violently around key news dates.
Benchmark metrics snapshot
On common benchmark metrics, AVCT often compares as follows versus healthcare‑sector averages:
- P/E ratio: Negative for AVCT vs. slightly negative or low‑positive for the broader sector.
- Price‑to‑book: Around 2.5–3.0x for AVCT vs. closer to 1.0–1.5x for the sector.
- Price‑to‑sales: Roughly 5–6x for AVCT vs. 3–4x for the comparables basket.
These comparisons highlight that investors are paying a premium for growth and optionality in AVCT rather than for current earnings or book value. That premium is justified only if the company succeeds in turning its platform and pipeline into real‑world drugs and diagnostics.
Forecasting the Avct share price
Analyst price targets
Several broker‑coverage providers publish Avct share‑price forecasts for Avacta Group. Consensus estimates for 12‑month price targets often sit well above the current level, implying a potential upside in the high‑teens to low‑hundreds of percent depending on the assumptions used. However, these targets are inherently speculative because:
- They depend heavily on unverified clinical outcomes and future partnership announcements.
- They assume no major setbacks in trials, financing, or regulatory approvals.
Even if the average target is above 100 pence, the actual path to that level could involve sharp drawdowns along the way, so investors should not treat the 12‑month forecast as a guaranteed outcome.
Scenario‑based thinking
A more realistic way to think about the Avct share price is via three‑way scenarios:
- Upside case (strong trial data, successful partnerships, no major financing shocks): AVCT could trade closer to, or above, its 2025 highs in the 80–90+ pence range.
- Base case (moderate progress, occasional setbacks, incremental partnerships): the stock might consolidate in the 60–80 pence band, with periodic spikes on news.
- Downside case (clinical failures, funding problems, or regulatory delays): the Avct share price could revisit or even break below 50 pence, and perhaps approach early‑2025 lows around 25–30 pence.
By mapping out these scenarios, investors can decide whether they are comfortable with the downside risk relative to the potential upside the Avct share price offers.
Frequently Asked Questions
Is American Virtual Cloud Technologies still trading in 2026?
No. The company was liquidated in 2023. Any “live” price you see for the US entity is likely a technical error on outdated financial platforms.
What should I do if I still have AVCTQ in my brokerage account?
If the ticker still appears with a zero value, it is likely just a placeholder. You should have already received a final statement to use for tax-loss harvesting, treating the security as worthless.
Why did Avacta Group’s shares drop in March 2026?
The price dipped roughly 3.5% to 66p because the company issued new shares at a 9.35% discount (63p) to raise £10 million for its clinical research.
Is Avacta Group related to the old American Virtual Cloud?
No. They are entirely separate entities that happen to share the same four-letter ticker symbol. One is a defunct US cloud firm; the other is an active UK biopharmaceutical leader.
Can I buy AVCT stock today?
You can buy Avacta Group PLC on the London Stock Exchange (AIM). You cannot buy the original American Virtual Cloud Technologies, as that legal entity no longer exists.
What is the “AVA6103” mentioned in 2026 news?
It is Avacta’s second major clinical program—a peptide drug conjugate designed to deliver potent anti-cancer drugs directly to tumors while reducing side effects.
Will the US AVCT ever come back?
No. The bankruptcy was a Chapter 11 Liquidation, not a reorganization. The assets were sold off, the debt was not fully covered, and the corporate shell was dissolved.
Final Thoughts
The investment landscape for “AVCT” in 2026 is defined by a complete divergence between two historically linked entities. For those holding the original American Virtual Cloud Technologies (formerly NASDAQ: AVCT), the story concluded in 2023 with a total loss of equity value following a Chapter 11 liquidation. The cancellation of these shares was a final legal event, meaning no “relisting” or recovery is possible for former US stockholders. The $6.8 million recovered from the sale of Kandy Communications was entirely absorbed by creditors, leaving zero proceeds for the equity class.
Conversely, the “AVCT” ticker is currently thriving on the London Stock Exchange, representing Avacta Group PLC. This company has moved into a high-growth phase in 2026, recently securing £10 million in new funding to accelerate its AVA6103 oncology program. With a current share price of approximately 66p and significant director-led investment, Avacta has effectively “reclaimed” the ticker symbol in the eyes of the global market. Investors must remain vigilant; while the technology once owned by the US firm (Kandy) lives on under Skyvera, the only tradable and appreciating asset under the “AVCT” name today is a UK-based leader in cancer therapeutics.
Read More on Newcastle Reporter